MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) CEO Rings Nasdaq Opening Bell

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games and toys in China, today announced that its CEO Xiaodong Chen rang the Nasdaq opening bell at 9:30 AM ET on August 30, 2019, signifying the start of today’s trade. BHAT executives, employees and directors joined Chen for the Market Bell Ceremony. “We are honored and excited to participate in the opening bell ceremony at Nasdaq,” BHAT CEO Xiaodong Chen said in the news release. “Our initial public offering completed in July 2019 represents a new start of our company, and we look forward to enhancing our user experience by launching innovative new products with our proprietary AR technology in the future.”

To view the full press release, visit http://ibn.fm/DnjZw

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of augmented reality (“AR”) interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. Its interactive entertainment platform brings unique user experience by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery.  Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, visit the company’s website at www.BlueHatGroup.net.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) Portfolio Company Acquires Ultra-Premium Cannabis Brand

Canopy Rivers (TSX.V: RIV) (OTC: CNPOF) on Thursday announced that its portfolio company TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) has entered definitive agreements to acquire ABI SF, LLC. ABI SF operates a Bay Area cannabis cultivation facility and owns the State Flower brand, which is recognized for its ultra-premium cannabis flower. California-based cannabis producer State Flower focuses on its craft approach to cultivation, using first-class genetics at an Envirocann certified facility in San Francisco. “This announcement is yet another example of TerrAscend delivering on its U.S. expansion plans, providing ever-growing U.S. exposure to Canopy Rivers’ and TerrAscend’s shareholder base,” Canopy Rivers president and CEO Narbe Alexandrian stated in the news release. “We think the acquisition of State Flower will allow TerrAscend to capture important mindshare in the U.S. through a strong, consumer facing brand. With a U.S. retail foothold already secured through The Apothecarium, we believe that State Flower is a natural strategic fit for TerrAscend.”

To view the full press release, visit http://ibn.fm/Sxhmk

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) Gains Media Attention Following Four Profitable Quarters

Organigram Holdings (TSX.V: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, recently received coverage in a Bloomberg article discussing OGI’s financial results for the last four quarters (http://ibn.fm/BUMhB). An article further discussing the company reads, “Organigram’s Q3 and fiscal year-to-date results represent some of the strongest operating and financial metrics amongst Canadian licensed producers. With one of the lowest cultivation costs per gram and continued discipline on selling, general and administrative expenses, Organigram’s results place it in the top tier of the Canadian industry. . . . As per the Bloomberg article, Organigram’s sustainable profitability is an outlier due to the fact that the industry has been experiencing some negative developments. Regulatory measures have been undertaken in Canada against some of the cultivators to ensure compliance. Other firms have been registering lower than expected sales, significant negative-adjusted EBITDA and shrinking margins in recent quarters.”

To view the full article, visit http://ibn.fm/HxtvU

About Organigram Holdings Inc.

Organigram Holdings is a TSX Venture Exchange and NASDAQ Global Select-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult-recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands including the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Investors.Organigram.ca.

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at  http://ibn.fm/OGRMF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Reports Positive Q2 2019 Financial Results

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, recently reported financial results for the second quarter ended June 30, 2019 (http://ibn.fm/shHin). An article discussing the company reads, “Apart from announcing strategic developments, INmune Bio also presented its most important financial results for the second quarter. Net loss attributable to common stockholders for the second quarter was $0.4 million, in comparison to $6.2 million for the same quarter of 2018. Research and development expenditure remained unchanged at $0.3 million. The total research and development expenditure was $0.6 million, but it was partially offset by a $0.3 million Alzheimer’s Association grant. . . . As of June 30, INmune Bio had cash and cash equivalents of $9.4 million with no debt. In May 2019, INmune closed a private placement of nearly $4.7 million. As of August 9, INmune Bio has 10.8 million common and 13.9 million fully diluted shares outstanding.”

To view the full article, visit http://ibn.fm/sT7d6

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that re-engineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Enters Recreational Cannabis Market, Fulfills Shipment to Ontario Cannabis Store

• The Green Organic Dutchman is a cannabis-focused research and development company
• The company recently completed its inaugural shipment to the Ontario Cannabis Store, marking its entry into the recreational cannabis market
• TGOD continues to explore strategic worldwide opportunities

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is a leading producer of premium, certified-organic cannabis. Licensed to cultivate medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), the company produces organic medical cannabis in small batches using all-natural, organic, craft-growing principles. TGOD recently entered into the recreational cannabis market, where consumers are seeking a premium organic product.

With head offices in Mississauga, Ontario, TGOD has a planned capacity of 219,000 kilograms and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. TGOD cultivates its cannabis in a proprietary living soil, without irradiation and in accordance with all-natural principles. The company’s growing process has earned organic certification from Pro-Cert and ECOCERT, both of which are leading organic certification organizations (http://ibn.fm/ZS9Ui).

TGOD’s hybrid facilities offer key advantages over outdoor, indoor and greenhouse facilities. Those advantages include advanced humidity, temperature and overall environmental controls relative to traditional greenhouses. Advantages also include highly automated and positive-pressure rooms that lessen the chance of contaminants.

TGOD recently completed its inaugural shipment to the Ontario Cannabis Store, officially marking the company’s entrance into Canada’s recreational market. In today’s increasingly competitive cannabis market, consumers are developing distinct preferences, especially for organic products. A recent study indicated that over 50 percent of consumers are looking for their cannabis to be organic (http://ibn.fm/MahYL), and Ontario consumers are now able to experience TGOD’s acclaimed Unite Organic dried flower. The company’s high-THC (tetrahydrocannabinol) signature strain is available on www.OCS.ca and at select retail locations across the province of Ontario (http://ibn.fm/IoeTF).

“We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers,” TGOD CEO Brian Athaide stated in a news release. “Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients. Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply.”

In addition, TGOD continues to provide its products to its medicinal patients throughout Canada. TGOD products were initially available only to a small group of medical patients known as the Grower’s Circle. Subsequently, the company also signed supply agreements with the provinces of Alberta and British Columbia.

Growing to scale, TGOD has unique partnerships in place. The company’s partners include international power-management company Eaton Corp., which provides research and optimization that will enable TGOD to have some of the lowest electricity input costs in the business. This is an essential step in the company’s plan to become one of the lowest-cost producers in Canada. Eaton designed TGOD’s power-management system, and TGOD purchases its power from HCE Energy, owned by the city of Hamilton, Ontario. TGOD utilizes Hydro-Quebec in Valleyfield. The company has another key partnership with construction-management firm Ledcor. The focus of this partnership is on ensuring logistical and infrastructure controls. Ledcor specializes in project and construction management, preconstruction services, design-build and general contracting. TGOD’s alliance partners, which also include Neptune, Mediakos and Symrise AG, are industry leaders, enabling the company to achieve its energy and production goals.

TGOD continues to focus on becoming the largest organic cannabis company in the world. By taking advantage of innovative technology and low-cost power solutions, the company offers investors the potential for substantial ROI. With its proven management team, TGOD is positioned for continued expansion and sales across North America, Latin America and Europe, especially considering its recent entry into the recreational cannabis market

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Organigram Holdings Inc.’s (TSX: OGI) (NASDAQ: OGI) Commitment to Corporate Governance, Fiscal Discipline a ‘Rarity in the Industry’

• Organigram’s corporate governance distinguishes the company in the cannabis industry
• OGI’s consistent financial performance positions it as an “anomaly in the Canadian cannabis market”
• The company recently upgraded from the TSX Venture Exchange to the Toronto Stock Exchange

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian licensed producer (LP) of premium-quality cannabis and extract-based products, is focused on producing high-quality, indoor-grown cannabis for patients and adult-recreational consumers. Championing that cause is Organigram’s leadership team, a group of seasoned professionals on the forefront of the global cannabis market who bring decades of experience in consumer-packaged goods, and pharma, including a CEO who held the same position at Tilray (NASDAQ: TLRY) before joining Organigram. In addition, the company’s fiscal discipline and execution, as well as its solid corporate governance foundation, distinguish it while some other LPs have met mild to severe consequences for regulatory breaches.

Bloomberg noted that OGI has a fully independent board of directors (excluding CEO Greg Engel), which is a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company. “This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards,” Engel told Bloomberg (http://ibn.fm/paDcr). “I think some of the challenges we’ve seen in the industry have been because of a lack of governance. You have to have independent governance that has oversight and holds management accountable.”

Along with the company’s impressive corporate governance comes its equally notable — and consistent — financial performance. This is likely due to its team’s adherence to fiscal discipline, something that can be difficult to find in this industry. Bloomberg noted that, with four quarters of profitability under its belt, Organigram Holdings is “an anomaly in the Canadian cannabis market.”

“Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production,” the report stated. “Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines. No other large Canadian pot producer has managed to post such a long string of positive EBITDA.”

In addition, the company recently uplisted to the Toronto Stock Exchange (TSX) from the TSX Venture Exchange (TSX.V) under the symbol ‘OGI’.

“Graduating to the TSX is a significant milestone for us as a corporation,” Engel stated in a news release (http://ibn.fm/g63Gj). “Our stakeholders have an eye on this marketplace, and this graduation will broaden our reach within the investment community and encourage new investors to learn more about our business, our growth plans and corporate objectives.”

As a result of many of these developments, OGI has attracted significant attention. OGI was deemed a “compelling cannabis stock to buy in August” in a recent article distributed by The Motley Fool (http://ibn.fm/3jeGk). “I continue to view the long-term prospects for Organigram in a favorable light,” contributor Keith Speights wrote. “Other Canadian cannabis producers get a lot more hype right now, but Organigram could be a rising star that will attract plenty of attention in the near future. What I really like about Organigram is that its management team exercises fiscal discipline, which is kind of a rarity in the industry.”

Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). Organigram has sales in all 10 Canadian provinces. The company has developed a portfolio of legal, adult-use recreational cannabis brands, including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Additionally, it delivers industry-leading yields and maximizes quality-cannabis production at one of the lowest cultivation costs per gram* among publicly reporting Canadian LPs. Organigram is committed to translating operational excellence into strong financial results and return on investment for shareholders.

* Cultivation cost per gram is a non-IFRS measure. Please see the Company’s latest MD&A.

For more information, visit the company’s website at www.Investors.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Acquires Second The+Source Location

Lifestyle-oriented cannabis company Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) today announced the closing of its acquisition of Henderson Organic Remedies, LLC (“The+Source Henderson”), which was previously disclosed on December 14, 2018. According to the update, the Henderson location is the second The+Source dispensary operated by GGB in greater Las Vegas, with similar productivity in both locations. “The+Source Henderson has been under our management for the last nine months,” Green Growth Brands CEO Peter Horvath said in the news release. “In that time, we have grown revenue, transactions and gross margin by double digits. Our ability to significantly improve top performing dispensaries, in a market that has seen a significant uptick in competition, is a testament to our expertise in retail operations.”

To view the full press release, visit http://ibn.fm/C881j

About Green Growth Brands

Green Growth Brands creates remarkable experiences in cannabis and CBD, led by CEO Peter Horvath and a leadership team of consumer-focused retail experts. The company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily and Meri + Jayne, with a licensing agreement with the Greg Norman Brand. Already boasting the strongest sales per square feet in the cannabis industry, GGB is expanding its presence in Nevada, Massachusetts and Arizona with CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. For more information, visit the company’s website at www.GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – TransCanna Holdings Inc.’s (CSE: TCAN) (FSE: TH8) Warrants Commence Trading on the CSE

TransCanna Holdings (CSE: TCAN) (FSE: TH8) this morning announced that 4,207,083 common share purchase warrants began trading on the Canadian Securities Exchange (“CSE”) under the symbol ‘TCAN.WT’ as the market opened today. The warrants, each of which entitle the holder to purchase one common share of the company, were issued in accordance with a private placement financing that closed in April 2019. The warrants will expire on April 4, 2022.

To view the full press release, visit http://ibn.fm/Vqk4t

About TransCanna Holdings Inc.

TransCanna Holdings is a Canadian-based company providing branding, transportation and distribution services, through its wholly owned California subsidiaries, to a range of industries including the cannabis marketplace. For more information, visit the company’s website at www.TransCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof.” These new patents include claims for DehydraTECH technology with respect to food and beverage use and also, for the first time, for pharmaceutical applications for delivery of cannabinoids as methods of treating certain conditions. These include, but are not limited to heart disease, neurological diseases, obesity, metabolic and appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine addiction.

To view the full press releases, visit http://ibn.fm/JemJa

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) Posts Q1 Fiscal 2020 Financial Results, Provides Corporate Update

Canopy Rivers (TSX.V: RIV) (OTC: CNPOF) this morning reported financial results for the first quarter ended June 30, 2019. Among other highlights, the company reported an operating income of $2.7 million for the quarter which it primarily attributes to royalty, interest and lease income. Canopy Rivers took advantage of new invest opportunities during the quarter, providing $18.8 million to new investments in Biolumic, Zeakal and High Beauty in addition to contributing a total of $6 million to existing investees Greenhouse Juice Company and Agripharm. “In Q1 2020, we made several exciting investments in plant sciences and cannabis brands, two areas that we think are primed for real growth in the cannabis sector,” Canopy Rivers President and CEO Narbe Alexandrian said in the news release. “In addition to our new investments, as lifecycle investors, it was also rewarding to see so much positive news coming from our portfolio companies this quarter. From PharmHouse entering into a significant supply agreement with Canopy Growth to TerrAscend becoming, to our knowledge, the first and, so far, only cannabis company with sales in Canada, the U.S., and the European Union, our portfolio companies were busy creating significant value.”

To view the full press release, visit http://ibn.fm/a8BJO

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Secures Agreement with Prominent Biotherapeutics Firm

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life-sciences and other industries, recently executed a contract services agreement with a well-known biotherapeutics firm. An article discussing the company reads, “Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://ibn.fm/aidN2). . . . PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often-challenging process of manufacturing the recombinant proteins that are required in the development of protein-based drugs. Two of the major challenges associated with manufacturing recombinant proteins are (1) the formation of aggregates and (2) protein misfolding. These are significant issues that can prevent a protein drug candidate from ever making it to market.”

To view the full article, visit http://ibn.fm/dKrgU

About Pressure BioSciences Inc.

Pressure BioSciences (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics-contract, research-services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Earth Science Tech Inc. (ETST) Launches Home Detection Kit Aimed at Improving Women’s Health

• Women’s health and access to medical amenities are huge concerns in both developed and developing nations
• ETST’s wholly owned subsidiary, Earth Science Pharm Inc., is dedicated to research, with a goal of eradicating STIs
• The company has launched Hygee, its home detection kits for screening STIs

Earth Science Tech Inc. (OTCQB: ETST) is a Florida-based biotech company engaged in the production of premium-quality industrial hemp and cannabis/cannabidiol (CBD) products. ETST offers 100 percent organic and pure CBD oil, which is made using the supercritical CO2 liquid-extraction process.

An innovative product aimed at improving women’s ability to self-screen for STIs was recently released by one of ETST’s subsidiaries. This kit, known as the Hygee, has the potential to revolutionize the arena of sexual health, empowering women through its innovative design.

Earth Science Pharma Inc., one of three wholly owned subsidiaries of ETST, is an emerging medical-research company engaged in the development of low-cost medical devices, testing processes, noninvasive diagnostic tools and vaccines for sexually transmitted infections and/or diseases (http://ibn.fm/WJSKk). The company’s research and development efforts are being conducted under the guidance and leadership of CEO and Chief Science Officer Michel Aube.

Earth Science Pharma is specifically focusing on developing and bringing to market medical devices and vaccines that focus on improving the health of women. Women’s health and access to medical amenities are huge concerns in both developed and developing nations. The company recently launched MSN-2, its first medical device, as a part of its initiative to meet the medical needs of women.

MSN-2 is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ETST named this innovative kit Hygee, after the French goddess of health (http://ibn.fm/ZQ2Zf). Hygee is a home-detection kit used for screening of STIs from a self-obtained gynecological specimen (http://ibn.fm/YLKCE). The kit includes a modified pantyliner, which is used to collect a sample of human cells that is sent to be analyzed in a laboratory using proven technology.

With MSN-2, modified pantyliners are worn by women for a duration of four hours – long enough to collect the specimen needed for laboratory tests. This kit can be ordered online and provides women with the ease of conducting tests in comfortable environments. Testing for STIs is essential for pregnant women, who must be screened for chlamydia infections to reduce the risk of transmitting the disease to their babies during childbirth.

The first production run of Hygee is underway, and initial marketing will target North America, South America, Asia and Africa. The company will package Hygee in English, French, Portuguese, Spanish, Vietnamese and Arabic in order to reach a wide audience of consumers.

“No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee,” Aube added in a news release (http://ibn.fm/kdJJ1). “With roughly 130 million new chlamydia cases diagnosed yearly, according to the [World Health Organization], Hygee is dedicated to this area of women’s health.”

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html